Marker Therapeutics Phase 1 APOLLO data: 66% ORR in NHL; 50% CR; dose expansion cleared

Marker Therapeutics, Inc.

66% objective response rate in NHL patients (8/12), with 50% complete response (6/12) at doses 100-200×10^6 cells.
No dose-limiting toxicities or ICANS observed; two Grade 1 CRS events (no treatment required).
Safety Review Committee cleared 400×10^6 cells max dose for DLBCL dose expansion in CAR-T relapsed/ineligible patients.
HL patients (n=9) showed 78% ORR (7/9) with 11% CR; median 8 prior lines of therapy.
Webcast August 26, 2025 at 8:30 am ET; next data update expected H1 2026.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-082783
form_type: 8-K
ticker: MRKR
cik: 0001094038
company_name: Marker Therapeutics, Inc.
filed_at: 2025-08-26T23:59:59+00:00
discovered_at: 2026-05-14T18:02:43.323213+00:00
generated_at: 2026-05-17T09:53:32.564493+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-082783
json_url: https://secwatch.observer/filing/0001104659-25-082783.json
markdown_url: https://secwatch.observer/filing/0001104659-25-082783.md
text_url: https://secwatch.observer/filing/0001104659-25-082783.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465925082783/0001104659-25-082783-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465925082783/tm2524197d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-082783

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.